India Slams USTR Report As An Attack On Low-Cost Generics

India’s government and domestic drugmakers have condemned the USTR’s move to keep the country on a ‘priority watch list’ over patentability criteria, intellectual-property protection and refusal to provide additional IP exclusivity.